title: Survival in patients with paraaortic lymph node metastases from endometrial adenocarcinoma clinically limited to the uterus.
abstract: OBJECTIVE
  The purpose of this study was (a) to evaluate the incidence of paraaortic lymph node metastasis from adenocarcinoma of the endometrium clinically limited to the uterus (1971 FIGO Stages I and II) and (b) to report the 5 year disease-free survival of patients with histologically documented paraaortic lymph node metastasis from endometrial adenocarcinoma clinically limited to the uterus treated on two separate protocols.
  
  
  METHODS
  From June 1979 to June 1990, 109 patients underwent staging paraaortic lymphadenectomy or paraaortic lymph node biopsy at the time of total abdominal hysterectomy and bilateral salpingo-oophorectomy for adenocarcinoma of the endometrium clinically limited to the uterus. Patients with histologically documented paraaortic lymph node metastasis were treated on two protocols: (a) pelvic radiation (5,040 cGy) plus progestins or (b) pelvic radiation therapy (5,040 cGy) plus paraaortic radiation (4,500 cGy).
  
  
  RESULTS
  Paraaortic lymph node metastases was primarily associated with grade 3 tumors (34.4%) and deep myometrial invasion (42%) and was present in 17.4% (19) of 109 patients. None of the women treated with pelvic radiation therapy and progestins survived five years disease-free. In contrast, the 5 year disease-free survival was 27% for patients treated by pelvic and paraaortic radiation.
  
  
  CONCLUSIONS
  Since all patients with macroscopic metastases to the paraaortic lymph nodes developed recurrent cancer and only a small percentage of those with microscopic metastases to the paraaortic lymph nodes survived disease-free at 5 years, improved survival for patients with paraaortic lymph node metastases will necessitate the addition of effective cytotoxic chemotherapy to pelvic and paraaortic radiation.
authors.affiliation: Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263.
authors.forename: M L
authors.initials: ML
authors.lastname: Hicks
authors.forename: M S
authors.initials: MS
authors.lastname: Piver
authors.forename: J L
authors.initials: JL
authors.lastname: Puretz
authors.forename: R E
authors.initials: RE
authors.lastname: Hempling
authors.forename: T R
authors.initials: TR
authors.lastname: Baker
authors.forename: M
authors.initials: M
authors.lastname: Mcauley
authors.forename: D L
authors.initials: DL
authors.lastname: Walsh
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology / Q000532:radiotherapy / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D016889:Endometrial Neoplasms / Q000453:epidemiology / Q000532:radiotherapy / Q000601:surgery*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D011372:Progestins / Q000627:therapeutic use; D011882:Radiotherapy, High-Energy; D014594:Uterine Neoplasms / Q000453:epidemiology / Q000532:radiotherapy / Q000601:surgery*
chemical_list: D011372:Progestins